Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the grant of conditional share awards on February 11, 2016, under the GlaxoSmithKline 2009 Performance Share Plan (PSP) and the 2009 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. Instead, it outlines specific financial targets used as performance metrics for executive compensation:
- Adjusted Free Cash Flow Target: The vesting schedule for one-third of the PSP awards is based on adjusted free cash flow targets ranging from a threshold of £11.6 billion to a maximum of £13.8 billion.
- Restructuring Costs: The free cash flow calculation adds back planned restructuring costs of £2.3 billion, which are funded separately from retained divestment proceeds.
- Share Pricing: Awards were valued using an Ordinary Share price of £13.59 (London Stock Exchange closing price on February 10, 2016) and an ADS price of $39.13 (New York Stock Exchange closing price on February 10, 2016).
Material Changes and Performance Measures
The filing details the structure of new equity incentives granted to Executive Directors and PDMRs, effective for the performance period of January 1, 2016, to December 31, 2018. The awards are subject to three equally weighted performance measures:
- Total Shareholder Return (TSR): Relative performance against a comparator group of nine other global pharmaceutical companies (including AstraZeneca, Pfizer, and Johnson & Johnson). Vesting begins at 44% if GSK ranks 5th (above median) and reaches 100% for ranks 1st through 3rd.
- Adjusted Free Cash Flow: Absolute performance targets ranging from £11.6 billion (25% vesting) to £13.8 billion (100% vesting).
- R&D New Product Performance: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at the threshold to 100% for performance exceeding 122% of the threshold.
Executive Directors face an additional two-year vesting period (five years total) compared to other PDMRs.
Guidance, Outlook, and Risks
The filing does not provide general business guidance or outlook. However, it highlights specific risks and contingencies related to the compensation plans:
- Performance Risk: If performance targets are not met, the conditional awards will lapse entirely or partially. For example, TSR awards vest at 0% if the company ranks 6th or below in the comparator group.
- Restructuring Contingency: The free cash flow metric is adjusted based on actual restructuring spend versus the planned £2.3 billion. Overspends or underspends will directly impact the vesting calculation.
- Forfeiture Risk: For Executive Directors, shares may be forfeited during the additional two-year vesting period if terminated for cause.
Investor Verification Checklist
- Verify the specific number of shares granted to each Executive Director and PDMR as listed in the filing tables.
- Confirm the composition of the TSR comparator group (AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings, Sanofi, and GSK).
- Monitor future disclosures for the specific R&D new product targets, which are currently withheld due to commercial sensitivity.
- Track the company's actual adjusted free cash flow and restructuring costs against the £11.6bn to £13.8bn targets to assess potential executive vesting.
- Note that this filing contains no operational financial results; refer to the company's annual or interim reports for revenue and profit data.